Diemen, Netherlands

Erik Hack

This inventor holds 2 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignees: Argenx Bv, Other. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Erik Hack. Retrieved from https://idiyas.com/inventor/erik-hack

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 50.0

 

Average Co-Inventor Count = 1.0

ph-index = 1

Forward Citations = 19(Granted Patents)


Company Filing History:


Years Active: 2013-2026

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Erik Hack - Innovator in Thrombus Prevention

Introduction

Erik Hack is a notable inventor based in Diemen, Netherlands. He has made significant contributions to the field of medicine, particularly in the area of thrombus prevention. His innovative work focuses on the use of anti-factor XI antibodies, which play a crucial role in inhibiting thrombus formation.

Latest Patents

Erik Hack holds a patent for the "Use of anti-factor XI antibodies for prevention of thrombus formation." This invention relates to binding molecules, such as antibodies, that specifically bind to plasma coagulation factor XI. These molecules inhibit factor XI activation and/or activity, providing methods for preventing or treating diseases and disorders mediated by factor XI activation. The beneficial effects of inhibiting factor XI are significant in the medical field.

Career Highlights

Throughout his career, Erik Hack has worked with various companies, including Argenx Bv. His expertise in the field has allowed him to contribute to advancements in medical research and therapeutic solutions.

Collaborations

Erik has collaborated with notable professionals in his field, including Christophe Blanchetot and Kevin Budding. These collaborations have further enhanced his research and development efforts.

Conclusion

Erik Hack's innovative work in the use of anti-factor XI antibodies represents a significant advancement in thrombus prevention. His contributions to the medical field highlight the importance of research and innovation in developing effective treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…